Amplia Announces Changes to Board's Leadership Roles

Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan. Dr Warwick Tong will retire as Board Chairman on 30 June 2026 and remain as a Non-Executive Director (NED) of the Company. Dr Tong has been a Director of Amplia since 4 May 2018 following the acquisition of Amplia Therapeutics Pty Ltd in April 2018. He was elected Chairman of the Board in August 2018. Ms Jane Bell AM was unanimously appointed Board Chair effective 30 June 2026 immediately following Dr Tong’s retirement. Ms Bell was appointed as an Independent Non-Executive Director of the Company on 12 April 2021 and is currently Chair of the Audit and Risk Committee. She has over two decades of experience as a Director with a particular focus in the Medical and Life Sciences sector as well as extensive banking and finance legal experience. Dr. Tong said, “It is a great privilege to serve on the Amplia Board and to help shape the Board and the Company over the past eight years. With the success of our recent clinical trials and increasing interest in the therapeutic potential of the portfolio it is an appropriate time to initiate changes in the Board and to prepare for new and exciting opportunities. I am delighted that the Board has appointed Jane to succeed me as Chair and she will bring her broad experience and strategic insights in the Life Sciences sector to the role.” Ms. Bell AM commented, “The Board is deeply grateful for Warwick’s exemplary leadership, expertise and dedicated service as Chair of Amplia through a period of evolution. Warwick’s significant commitment to drug discovery and drug development as well as to building part...